ANI Pharmaceuticals (Germany) Today
| BSFA Stock | 52.50 1.00 1.94% |
Performance0 of 100
| Odds Of DistressLess than 32
|
ANI Pharmaceuticals is selling for under 52.50 as of the 13th of January 2025; that is 1.94 percent increase since the beginning of the trading day. The stock's last reported lowest price was 51.5. ANI Pharmaceuticals has about a 32 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 14th of December 2024 and ending today, the 13th of January 2025. Click here to learn more.
Moving against ANI Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
ANI Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ANI Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ANI Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) |
ANI Pharmaceuticals (BSFA) is traded on Stuttgart Exchange in Germany and employs 601 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 699.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ANI Pharmaceuticals's market, we take the total number of its shares issued and multiply it by ANI Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ANI Pharmaceuticals operates under Healthcare sector and is part of Drug Manufacturers-Specialty & Generic industry. The entity has 17.45 M outstanding shares.
ANI Pharmaceuticals generates positive cash flow from operations, but has no cash available
Check ANI Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationANI Pharmaceuticals holds a total of 17.45 Million outstanding shares. The majority of ANI Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ANI Pharmaceuticals to benefit from reduced commissions. Thus, institutional investors are subject to a different set of regulations than regular investors in ANI Pharmaceuticals. Please pay attention to any change in the institutional holdings of ANI Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check ANI Ownership Details
ANI Pharmaceuticals Risk Profiles
Although ANI Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate ANI Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.52 | |||
| Semi Deviation | 1.75 | |||
| Standard Deviation | 2.0 | |||
| Variance | 4.01 |
ANI Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in ANI Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
ANI Pharmaceuticals Corporate Management
Elected by the shareholders, the ANI Pharmaceuticals' board of directors comprises two types of representatives: ANI Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ANI. The board's role is to monitor ANI Pharmaceuticals' management team and ensure that shareholders' interests are well served. ANI Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ANI Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nikhil Lalwani | CEO Pres | Profile | |
| Meredith Cook | Gen VP | Profile | |
| Chad Gassert | Sr Strategy | Profile | |
| Elizabeth JD | Chief Disease | Profile | |
| James Marken | VP Devel | Profile | |
| Ori Gutwerg | VP Generics | Profile | |
| Stephen Carey | Sr CFO | Profile |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.